Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051204133> ?p ?o ?g. }
- W2051204133 endingPage "194" @default.
- W2051204133 startingPage "189" @default.
- W2051204133 abstract "Objective To describe the change in serum prolactin concentrations in elderly agitated nursing home patients with dementia who were newly initiated on olanzapine or switched to olanzapine treatment from either conventional antipsychotics or risperidone. Methods During an 8-week open-label olanzapine efficacy trial in elderly nursing home patients demonstrating clinically significant behavioral and psychological symptoms of dementia, serum prolactin concentrations were drawn on four occasions: at time of consent, following a washout period from previous therapy, midway through the study, and at endpoint. To assess post-hoc the effects of prolactin concentrations upon switching to olanzapine treatment, patients were divided into three different groups, based upon status at time of consent: those not taking antipsychotic medication, those taking any conventional antipsychotic, and those taking risperidone. Prolactin concentrations were assessed using a mixed-effect repeated-measures model. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS), the Cohen-Mansfield Agitation Inventory (CMAI), the Clinical Global Impression (CGI)-Severity scale, and the Mini-Mental State Examination (MMSE), and the same repeated measures analysis was performed on these scales. Results Patients not on antipsychotic medication at study entry (29 females, 7 males) experienced a significant increase in prolactin concentration baseline to endpoint (P < 0.05) but remained below upper limit of normal for prolactin for both males and females. There was a nonsignificant increase in prolactin concentrations when patients were switched from conventional antipsychotic medications (mean dose 152.41 ± 192.48 mg/day chlorpromazine equivalents) to olanzapine (2.5 to 10 mg/day) (22 females, 9 males). Patients who entered the study on risperidone (mean dose 1.31 ± 0.91 mg/day) (13 females, 4 males) experienced a significant decrease in prolactin concentration (P < 0.001). While 62.5% of risperidone-treated patients had above-normal prolactin concentrations at baseline, only 21.4% had above-normal concentrations at endpoint (P = 0.033). Clear correlations between prolactin concentrations and clinical outcomes could not be determined. Conclusion Consistent with previous findings in younger patients, olanzapine appeared to be a prolactin-sparing antipsychotic medication in the elderly with only modest prolactin increases observed. In addition, patients who were receiving risperidone and then switched to olanzapine experienced a significant reduction in prolactin concentrations that was sustained over the 8-week treatment course with olanzapine. One possible explanation for olanzapine's relatively modest increase in prolactin is that, unlike conventionals or risperidone, olanzapine binds less tightly with the dopamine D2 receptor. To describe the change in serum prolactin concentrations in elderly agitated nursing home patients with dementia who were newly initiated on olanzapine or switched to olanzapine treatment from either conventional antipsychotics or risperidone. During an 8-week open-label olanzapine efficacy trial in elderly nursing home patients demonstrating clinically significant behavioral and psychological symptoms of dementia, serum prolactin concentrations were drawn on four occasions: at time of consent, following a washout period from previous therapy, midway through the study, and at endpoint. To assess post-hoc the effects of prolactin concentrations upon switching to olanzapine treatment, patients were divided into three different groups, based upon status at time of consent: those not taking antipsychotic medication, those taking any conventional antipsychotic, and those taking risperidone. Prolactin concentrations were assessed using a mixed-effect repeated-measures model. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS), the Cohen-Mansfield Agitation Inventory (CMAI), the Clinical Global Impression (CGI)-Severity scale, and the Mini-Mental State Examination (MMSE), and the same repeated measures analysis was performed on these scales. Patients not on antipsychotic medication at study entry (29 females, 7 males) experienced a significant increase in prolactin concentration baseline to endpoint (P < 0.05) but remained below upper limit of normal for prolactin for both males and females. There was a nonsignificant increase in prolactin concentrations when patients were switched from conventional antipsychotic medications (mean dose 152.41 ± 192.48 mg/day chlorpromazine equivalents) to olanzapine (2.5 to 10 mg/day) (22 females, 9 males). Patients who entered the study on risperidone (mean dose 1.31 ± 0.91 mg/day) (13 females, 4 males) experienced a significant decrease in prolactin concentration (P < 0.001). While 62.5% of risperidone-treated patients had above-normal prolactin concentrations at baseline, only 21.4% had above-normal concentrations at endpoint (P = 0.033). Clear correlations between prolactin concentrations and clinical outcomes could not be determined. Consistent with previous findings in younger patients, olanzapine appeared to be a prolactin-sparing antipsychotic medication in the elderly with only modest prolactin increases observed. In addition, patients who were receiving risperidone and then switched to olanzapine experienced a significant reduction in prolactin concentrations that was sustained over the 8-week treatment course with olanzapine. One possible explanation for olanzapine's relatively modest increase in prolactin is that, unlike conventionals or risperidone, olanzapine binds less tightly with the dopamine D2 receptor." @default.
- W2051204133 created "2016-06-24" @default.
- W2051204133 creator A5010145606 @default.
- W2051204133 creator A5015085334 @default.
- W2051204133 creator A5018064651 @default.
- W2051204133 creator A5073010399 @default.
- W2051204133 creator A5083279464 @default.
- W2051204133 creator A5091703998 @default.
- W2051204133 date "2003-07-01" @default.
- W2051204133 modified "2023-09-30" @default.
- W2051204133 title "The Effects of Antipsychotic Drug Treatment on Prolactin Concentrations in Elderly Patients" @default.
- W2051204133 cites W122505910 @default.
- W2051204133 cites W1741266477 @default.
- W2051204133 cites W175660244 @default.
- W2051204133 cites W1787454655 @default.
- W2051204133 cites W1821730900 @default.
- W2051204133 cites W1847168837 @default.
- W2051204133 cites W1979634878 @default.
- W2051204133 cites W1983133139 @default.
- W2051204133 cites W1984137501 @default.
- W2051204133 cites W1988730265 @default.
- W2051204133 cites W1996587316 @default.
- W2051204133 cites W1998673996 @default.
- W2051204133 cites W2011846252 @default.
- W2051204133 cites W2013902956 @default.
- W2051204133 cites W2019879674 @default.
- W2051204133 cites W2022528197 @default.
- W2051204133 cites W2028386029 @default.
- W2051204133 cites W2031395338 @default.
- W2051204133 cites W2033734081 @default.
- W2051204133 cites W2038901045 @default.
- W2051204133 cites W2049790055 @default.
- W2051204133 cites W2060802427 @default.
- W2051204133 cites W2064797152 @default.
- W2051204133 cites W2067235029 @default.
- W2051204133 cites W2067345339 @default.
- W2051204133 cites W2081095472 @default.
- W2051204133 cites W2099576957 @default.
- W2051204133 cites W2101052738 @default.
- W2051204133 cites W2152953527 @default.
- W2051204133 cites W2333793022 @default.
- W2051204133 cites W2402377475 @default.
- W2051204133 cites W4251508433 @default.
- W2051204133 cites W69700487 @default.
- W2051204133 doi "https://doi.org/10.1016/s1525-8610(04)70344-8" @default.
- W2051204133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12837139" @default.
- W2051204133 hasPublicationYear "2003" @default.
- W2051204133 type Work @default.
- W2051204133 sameAs 2051204133 @default.
- W2051204133 citedByCount "23" @default.
- W2051204133 countsByYear W20512041332012 @default.
- W2051204133 countsByYear W20512041332014 @default.
- W2051204133 countsByYear W20512041332016 @default.
- W2051204133 countsByYear W20512041332017 @default.
- W2051204133 countsByYear W20512041332019 @default.
- W2051204133 countsByYear W20512041332021 @default.
- W2051204133 countsByYear W20512041332022 @default.
- W2051204133 countsByYear W20512041332023 @default.
- W2051204133 crossrefType "journal-article" @default.
- W2051204133 hasAuthorship W2051204133A5010145606 @default.
- W2051204133 hasAuthorship W2051204133A5015085334 @default.
- W2051204133 hasAuthorship W2051204133A5018064651 @default.
- W2051204133 hasAuthorship W2051204133A5073010399 @default.
- W2051204133 hasAuthorship W2051204133A5083279464 @default.
- W2051204133 hasAuthorship W2051204133A5091703998 @default.
- W2051204133 hasConcept C118552586 @default.
- W2051204133 hasConcept C126322002 @default.
- W2051204133 hasConcept C142724271 @default.
- W2051204133 hasConcept C204787440 @default.
- W2051204133 hasConcept C27081682 @default.
- W2051204133 hasConcept C2776000289 @default.
- W2051204133 hasConcept C2776412080 @default.
- W2051204133 hasConcept C2776619155 @default.
- W2051204133 hasConcept C2778528637 @default.
- W2051204133 hasConcept C2778775820 @default.
- W2051204133 hasConcept C2779064019 @default.
- W2051204133 hasConcept C2779727114 @default.
- W2051204133 hasConcept C2780057945 @default.
- W2051204133 hasConcept C2780494398 @default.
- W2051204133 hasConcept C67761136 @default.
- W2051204133 hasConcept C71315377 @default.
- W2051204133 hasConcept C71924100 @default.
- W2051204133 hasConceptScore W2051204133C118552586 @default.
- W2051204133 hasConceptScore W2051204133C126322002 @default.
- W2051204133 hasConceptScore W2051204133C142724271 @default.
- W2051204133 hasConceptScore W2051204133C204787440 @default.
- W2051204133 hasConceptScore W2051204133C27081682 @default.
- W2051204133 hasConceptScore W2051204133C2776000289 @default.
- W2051204133 hasConceptScore W2051204133C2776412080 @default.
- W2051204133 hasConceptScore W2051204133C2776619155 @default.
- W2051204133 hasConceptScore W2051204133C2778528637 @default.
- W2051204133 hasConceptScore W2051204133C2778775820 @default.
- W2051204133 hasConceptScore W2051204133C2779064019 @default.
- W2051204133 hasConceptScore W2051204133C2779727114 @default.
- W2051204133 hasConceptScore W2051204133C2780057945 @default.
- W2051204133 hasConceptScore W2051204133C2780494398 @default.
- W2051204133 hasConceptScore W2051204133C67761136 @default.
- W2051204133 hasConceptScore W2051204133C71315377 @default.